According to the Complaint, Zynerba Pharmaceuticals, Inc. was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba operates as a clinical stage specialty pharmaceutical company. The Company focuses on developing pharmaceutically-produced transdermal CBD therapies for rare and near-rare neuropsychiatric disorders.
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.